trending Market Intelligence /marketintelligence/en/news-insights/trending/lG5AQS0Gedj2MAxycE2vaw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cascadian Therapeutics to raise $82.5M in public offerings

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cascadian Therapeutics to raise $82.5M in public offerings

Cascadian Therapeutics Inc. is looking to raise approximately $82.5 million in two concurrent underwritten offerings.

The company priced an offering of 23,182,000 common stock at $3.30 apiece to raise $76.5 million; Cascadian will also issue 1,818 series E preferred stock at $3,300 per share to raise another $6 million.

Each series E preferred stock is convertible into 1,000 Cascadian shares. Underwriters have an option to purchase an additional 3,477,300 of the shares offered.

The offering is expected to close Jan. 27 and will help fund the clinical trial of Tucatinib for the treatment of breast cancer.

Cowen and Co. LLC and Barclays Capital Inc. are acting as joint book-running managers of the issue, with Raymond James & Associates Inc. acting as lead manager and BTIG LLC acting as a co-manager.